Welcome back to our scientific resources section of our blog, where we focus on cutting-edge discoveries. Today, we are thrilled to share with you a presentation delivered by none other than our Chief Scientific Officer, Dr Agapitos Patakas, at the prestigious PEGS Boston 2023 conference.
The number of antibody-targeted immuno-oncology therapeutics in development is growing year on year, yet there persists a lack of in vitro systems to interrogate the efficacy and safety of these modalities. In the following presentation, Dr Patakas will describe our IndEx-2 system, an in vitro cell-based platform which allows the expression of one, or two, target antigens over a range of biologically relevant levels. This system allows the determination of the precise antigen density activation thresholds of targeted candidate immunotherapies, enabling selection of candidates with improved efficacy and enhanced safety profiles at the discovery stage.
Without further ado, let’s delve into the realm of IndEx-2 and its implications for immune-directed therapies, as presented by Dr Agapitos Patakas; watch our video.
If you have any questions on IndEx-2 or would like to talk to our scientists, feel free to book a meeting with them.
Stay tuned for more video content and other scientific resources on our blog.
Related articles
Target cells are a critical component of immune cell effector assays. Whether investigating T cell dependent cellular cytotoxicity (TDCC) or antibody dependent cellular cytotoxicity (ADCC), we create engineered target cells uniquely suited for the evaluation of effector function and molecule specificity. But how do we achieve this and what are the principles we follow?
Our latest new development is the launch of our transformative inducible cell line development platform: IndEx-2.
In this webinar, we present our own human in vitro T cell exhaustion model that is suitable for the screening of immuno-modulatory molecules, bispecific T cell engagers and multi-functional modalities.